Le Journal

Warning: This article includes descriptions of self-harm. After a family sued OpenAI saying their teenager used ChatGPT as his “suicide coach,” the company responded on Tuesday saying it is not liable for his death, arguing that the boy misused the chatbot. The legal response, filed in California Superior Court in San Francisco, is OpenAI’s first answer to a lawsuit that sparked widespread concern over the potential mental health harms that chatbots can pose. In August, the parents of 16-year-old Adam Raine sued OpenAI and its CEO Sam Altman, accusing the company behind ChatGPT of wrongful death, design defects and failure to warn of risks associated with the chatbot. Chat logs in the lawsuit showed that GPT-4o — a version of ChatGPT known for being especially affirming and sycophantic — actively discouraged him from seeking mental health help, offered to help him write a suicide note and even advised him on his noose setup. “To the extent that any ‘cause’ can be attributed to this tragic event,” OpenAI argued in its court filing, “Plaintiffs’ alleged injuries and harm were caused or contributed to, directly and proximately, in whole or in part, by Adam Raine’s misuse, unauthorized use, unintended use, unforeseeable use, and/or improper use of ChatGPT.” The company cited several rules within its terms of use that Raine appeared to have violated: Users under 18 years old are prohibited from using ChatGPT without consent from a parent or guardian. Users are also forbidden from using ChatGPT for “suicide” or “self-harm,” and from bypassing any of ChatGPT’s protective measures or safety mitigations. When Raine shared his suicidal ideations with ChatGPT, the bot did issue multiple messages containing the suicide hotline number, according to his family’s lawsuit. But his parents said their son would easily bypass the warnings by supplying seemingly harmless reasons for his queries, including by pretending he was just “building a character.” OpenAI’s new filing in the case also highlighted the “Limitation of liability” provision in its terms of use, which has users acknowledge that their use of ChatGPT is “at your sole risk and you will not rely on output as a sole source of truth or factual information.” Jay Edelson, the Raine family’s lead counsel, wrote in an email statement that OpenAI’s response is “disturbing.” “They abjectly ignore all of the damning facts we have put forward: how GPT-4o was rushed to market without full testing. That OpenAI twice changed its Model Spec to require ChatGPT to engage in self-harm discussions. That ChatGPT counseled Adam away from telling his parents about his suicidal ideation and actively helped him plan a ‘beautiful suicide.’ And OpenAI and Sam Altman have no explanation for the last hours of Adam’s life, when ChatGPT gave him a pep talk and then offered to write a suicide note,” Edelson wrote. (The Raine family’s lawsuit claimed that OpenAI’s “Model Spec,” the technical rulebook governing ChatGPT’s behavior, had commanded GPT-4o to refuse self-harm requests and provide crisis resources, but also required the bot to “assume best intentions” and refrain from asking users to clarify their intent.) Edelson added that OpenAI instead “tries to find fault in everyone else, including, amazingly, saying that Adam himself violated its terms and conditions by engaging with ChatGPT in the very way it was programmed to act.” OpenAI’s court filing argued that the harms in this case were at least partly caused by Raine’s “failure to heed warnings, obtain help, or otherwise exercise reasonable care,” as well as the “failure of others to respond to his obvious signs of distress.” It also shared that ChatGPT provided responses directing the teenager to seek help more than 100 times before his death on April 11, but that he attempted to circumvent those guardrails. “A full reading of his chat history shows that his death, while devastating, was not caused by ChatGPT,” the filing stated. “Adam stated that for…

The New Haven Steelers are gearing up for the national championship game in Charlotte, North Carolina next month, but they need help getting there. Over the next week, the Pop Warner youth football team is raising money for transportation, hotel and food for 29 players. The federal grant they rely on was cut in half this year, so their fundraising goal has doubled to a total of $38,000. As back-to-back regional champions, the team has been working extra hard, even in Tuesday evening’s pouring rain, to make it all the way this year. “We started in the summertime, mid-July, heat index is 90 plus, we have rainy days like today, windy days, but we’re out here,” Leonard Jahad, the New Haven Steelers vice president, said. “The kids have really worked hard, not only in the football field, but also school. We have scholar athletes.” Jahad added that the players would receive tutoring for the 10 days they’re in Charlotte so there isn’t a gap in learning. The team advancing to nationals is made up of 12- and 13-year-old boys. “For some of these kids, just making it out of Connecticut is a big thing,” Cameron Davis, New Haven Steelers offensive and defensive line coach, said. “So with them going down there and being able to showcase their skills, their athleticism, that means a lot to them.” The Pop Warner Super Bowl and National Championships start Dec. 6 in Charlotte, North Carolina. The team is collecting donations here.

The Centers for Medicare and Medicaid Services on Tuesday announced lower prices on 15 costly prescription drugs under Medicare, including Ozempic and Wegovy. The price cuts come through the Medicare drug price negotiation program created under the Inflation Reduction Act, which President Joe Biden signed into law in 2022. It’s different from President Donald Trump’s “most favored nation” drug pricing approach, which relies on executive orders and voluntary deals with drugmakers — not legislation. Trump recently announced such a deal with Novo Nordisk, the maker of Ozempic and Wegovy, to lower the price of the drugs in exchange for tariff relief. The Trump administration has been largely quiet about the Medicare price negotiation program. Centers for Disease Control and Prevention 7 hours ago Controversial Louisiana surgeon general tapped for CDC leadership role Health & Science 11 hours ago After CDC changes messaging on debunked autism–vaccine link, doctors answer parents' top questions Marijuana 9 hours ago It's possible to get addicted to marijuana. Here's what to know This marks the second round of negotiations. Last year, the Biden administration reached deals on 10 prescription drugs, including several for heart disease and diabetes. Those price cuts are set to take effect in 2026. This latest round of price negotiations will go into effect in 2027. “President Trump directed us to stop at nothing to lower health care costs for the American people,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a press release. “As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors.” Drugmakers can choose not to strike deals under the negotiation program, but doing so would likely mean withdrawing their drugs from Medicare — cutting them off from one of the nation’s largest markets. Drugmakers have challenged the program in court but so far have been unsuccessful. The negotiated prices are what Medicare will pay drugmakers for the medicines, not what patients will pay out of pocket. Those discounts will save taxpayers $12 billion, according to CMS. It’s expected to save Medicare enrollees $685 million in out of pocket costs in 2027. Here are the negotiated prices for the drugs, based on a 30-day supply, compared to the 2024 list price: Ozempic, Rybelsus and Wegovy, for Type 2 diabetes and weight loss: $274 negotiated price, down from the $959 list price. (Negotiated prices for higher doses of Wegovy are $385.) Trelegy Ellipta, an asthma treatment: $175, down from $654. Xtandi, for prostate cancer: $7,004, down from $13,480. Pomalyst, a chemotherapy drug: $8,650, down from $21,744. Ofev, for idiopathic pulmonary fibrosis: $6,350, down from $12,622. Ibrance, a breast cancer drug: $7,871, down from $15,741. Linzess, a chronic constipation drug: $136, down from $539. Calquence, a cancer drug: $8,600, down from $14,228. Austedo and Austedo XR, for Huntington’s disease: $4,093, down from $6,623. Breo Ellipta, a COPD drug: $67, down from $397. Xifaxan, for diarrhea and irritable bowel syndrome: $1,000, down from $2,696. Vraylar, an antipsychotic drug: $770, down from $1,376. Tradjenta, a diabetes drug: $78, down from $488. Janumet and Janumet XR, diabetes drugs: $80, down from $526. Otezla, a psoriatic arthritis drug: $1,650, down from $4,722. The 15 drugs accounted for $42.5 billion, or 15%, of total Medicare Part D spending in 2024. Medicare Part D covers medications that people take at home, as opposed to those administered in a facility, such as IV chemotherapy. “The price negotiations look very reasonable to me,” Stacie Dusetzina, a health policy professor at Vanderbilt University in Nashville, Tennessee. “It should hopefully provide some relief for taxpayers and beneficiaries in the long run.” Dusetzina said the $274 negotiated price for Ozempic and Wegovy is higher than the $250 price in Trump’s deal. “They should’ve gotten that deal for the…

The Boston Red Sox made a stark improvement to their pitching rotation by acquiring Sonny Gray in a trade with the St. Louis Cardinals. However, the Red Sox’s roster is far from being completed. There is still the free agency of Alex Bregman to worry about. After a year in Boston, the Red Sox must decided if they want to bring him back on a more expensive contract. Even if they opt to, they need at least one more big bat in their lineup. But even after the Gray trade, Boston shouldn’t stop adding to their pitching rotation. Gray is a strong starter, with 160+ innings pitched and 200+ strikeouts in his two seasons wit the Cardinals. Still, the Red Sox should shoot even higher when trying to find their No. 2 starter behind ace Garrett Crochet. Prior to the trade deadline, Boston showed immense trade interest in Minnesota Twins starter Joe Ryan. As they continue configuring their pitching rotation, the Red Sox should give the Twins another call. Red Sox must target Twins ace Joe Ryan Matt Krohn-Imagn Images Over his five years with the Twins, Ryan has put up a 3.79 ERA and a 719/148 K/BB ratio. He is coming off of the best season of his career, earning his first All-Star nomination. The right-hander registered a career-best 3.42 ERA alongside a 194/39 K/BB ratio. If Ryan were on the Red Sox, he would’ve ranked just behind Brayan Bello for third-best ERA among pitchers with 20+ starts. He beat out Bello by 70 strikeouts though, which would’ve put him behind just Crochet. Acquiring Ryan would be beneficial for Boston in both the short and long-term. The righty isn’t a free agent until after the 2027 season. Furthermore, he is still arbitration eligible meaning his contract will be modest. The Red Sox would still be able to add Bregman or whichever big bat they choose while massively bolstering their roster. If Ryan continues his All-Star play up, the Red Sox would then have a dangerous one-two punch atop of their rotation. Bello would then be the third starter with Gray slotting in at fourth. For a team seemingly always in need of pitching, Boston would then have one of the scarier rotations in the league. Maybe Gray is the only pitcher the Red Sox wanted to acquire. However, Boston knows they need much more to truly compete for a World Series title. Trading for Ryan would prove the Red Sox are serious about remaining in the playoffs. Furthermore, it would give Boston another elite pitcher in their rotation. The post Next trade Red Sox must make after acquiring Sonny Gray from Cardinals appeared first on ClutchPoints.

Arkansas senior Sydney Vaught was named the 2025 USTFCCCA South Central Region Athlete of the Year in cross country via voting by coaches. This marks the third consecutive year for a Razorback to receive the women’s honor.